Xeris Pharmaceuticals | XERS - Current Assets


Xeris Pharmaceuticals reported $289.26M in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Celltrion KRW 493.66B 12.09B Jun/2026
Cspc Pharmaceutical CNY 22.25B 359.48M Dec/2025
Deva Holding AS TRY 9.13B 1.61B Sep/2023
Dianthus Therapeutics USD 856.04M 41.5M Sep/2026
Divis Laboratories Ltd INR 124.39B 13.43B Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
Kangmei Pharma CNY 6.66B 143.43M Jun/2026
Knight Therapeutics CAD 394.84M 5.86M Dec/2025
Laboratorios Farma EUR 509.33M 128.63M Dec/2023
Malin Corporation EUR 62.6M 26.7M Dec/2024
Medical Developments International AUD 33.75M 1.79M Dec/2025
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neuren Pharmaceuticals AUD 332.23M 11.98M Dec/2025
Organigram Holdings CAD 280.09M 30M Jun/2026
Ovoca Bio EUR 2.07M 510K Dec/2025
Pacira USD 10.3B 9.68B Sep/2026
Perrigo USD 2.4B 49.7M Sep/2026
Pharma Mar EUR 295.56M 14.62M Sep/2026
Qiagen NV USD 1.66B 116.37M Jun/2026
Sartorius EUR 1.65B 8.4M Sep/2026
Sino Biopharmaceutical CNY 33.82B 9.13B Jun/2025
Supernus Pharmaceuticals USD 711.21M 12.28M Sep/2026
Tilray USD 729.32M 28.18M Sep/2025
Zealand Pharma A/S 15.02B 652.12M Mar/2026
Zz Pientze Pharmaceu CNY 13.48B 2.32B Sep/2026